A brief history of Tomorrow.bio

Tomorrow.bio began with a simple question: if future medicine can reverse the causes of death, why shouldn’t people have the chance to reach that future? The company was founded in 2020 with the goal of offering human cryopreservation as a medical service, carried out with clear procedures, trained staff, and long-term stability. What started as a small team with a focused mission has grown into one of the main cryonics providers in the world.

The idea behind the company came from Dr Emil Kendziorra. Before Tomorrow.bio, he worked in cancer and longevity research. He saw how long it takes for new treatments to reach patients. Even when early results look promising, progress can slow down for many reasons. For Emil, cryopreservation offered a way for people to reach a future where better treatments might exist. It was not a guarantee, but it offered a chance.

To build a working cryonics company, he needed someone with strong operational and engineering skills. That is where Fernando Azevedo Pinheiro entered the picture. Fernando’s background includes industrial and civil engineering as well as experience launching technology companies. Together, they created a structure that combines medical expertise, engineering, logistics and long-term planning.

From the start, Tomorrow.bio aimed to make cryopreservation clear and accessible. The company set up its main office in Berlin. For long-term storage, they partnered with the European Biostasis Foundation (EBF) in Switzerland. The foundation maintains the dewars, manages the storage facility, and ensures that patients remain cryopreserved in safe, stable conditions for as long as needed.

Tomorrow.bio did not begin with the scale it has today. The early years focused on building the right procedures, training personnel and forming a medical standby team. Cryopreservation is time-sensitive, so teams must act soon after legal death. That means planning, readiness, and equipment matter. The company developed a standby program with trained specialists who can travel to patients, stabilize the body, and prepare it for transport.

As the procedures solidified, membership grew. People from many countries began to sign up. Today, Tomorrow.bio has more than 800 members across more than 45 countries and over 200 cities. The company also maintains several patients, both human and animal, already in cryopreservation.

One major step in the company’s history was its expansion to the United States in 2024. The U.S. has shown long-standing interest in cryonics, and many people there look for services that combine medical readiness with European standards. Tomorrow.bio now offers U.S. patients the same procedures and storage conditions available in Europe, with the exception of brain-only cryopreservation

Despite its growth, Tomorrow.bio continues to repeat one point: cryopreservation is not a promise of revival. It is a chance. No one knows when future medicine will gain the ability to reverse death conditions. The service exists so that people who want that chance can choose it.

Another defining trait of ours is the focus on transparency. Many people approach cryonics with questions about ethics, legality, religion, and family decisions. The company shares information about all vsteps, costs, and limitations. This reflects the founders’ view that people deserve clear knowledge before they make such a personal choice.

The long-term side of cryopreservation also shapes the company’s structure. Cryonics only works if the organization can last beyond normal business cycles. That is why the partnership with the European Biostasis Foundation matters. The foundation manages funding, storage, and governance built to survive changes in leadership or markets.

As the field continues to grow, Tomorrow.bio’s history shows how a clear mission and a focus on honest communication can shape a service that deals with life, death and the uncertain territory between them.More on our R&D here.